How Lamzede Works in Mannosidosis
Lamzede (velmanase alfa-tylv) is an enzyme replacement therapy (ERT) approved for treating non-central nervous system manifestations of alpha-mannosidosis, a rare lysosomal storage disorder caused by deficiency of the enzyme alpha-mannosidase. This deficiency leads to buildup of mannose-rich oligosaccharides in cells, causing tissue damage, skeletal abnormalities, hearing loss, infections, and developmental delays.[1]
Lamzede provides the missing recombinant human alpha-mannosidase enzyme via intravenous infusion every two weeks. The enzyme is taken up by cells through mannose-6-phosphate receptors, enters lysosomes, and breaks down accumulated substrates, reducing oligosaccharidosis and improving cellular function.[1][2]
What Symptoms Does It Target?
It addresses peripheral symptoms like skeletal dysplasia (dysostosis multiplex), mild to moderate hearing impairment, recurrent infections, and motor function limitations. It does not cross the blood-brain barrier, so it has no effect on central nervous system issues like cognitive impairment.[1]
Clinical Evidence of Effectiveness
In the pivotal Phase 3 trial (24 months, 39 patients aged 6+), Lamzede reduced urinary oligosaccharide levels by 24-58% (dose-dependent) and improved 3-minute walk test distances by 28-37 meters versus placebo. Glycoprotein clearance also increased. Long-term data from extensions show sustained benefits in mobility and pulmonary function.[2][3]
How Is It Administered?
Starting dose is 1 mg/kg IV every two weeks, potentially increasing to 2 mg/kg based on response. Infusions last 4+ hours in a clinical setting, with monitoring for hypersensitivity.[1]
What Are Common Side Effects?
Most are mild: headache (29%), fever (21%), infusion reactions (19% like nausea, vomiting). Anaphylaxis is rare but possible; pre-medication with antihistamines/corticosteroids may be used.[1]
Who Makes Lamzede and Availability?
Chiesi Global Rare Diseases manufactures it. FDA approved in March 2021 for patients 6 years and older; EMA approved in 2020. It's orphan drug designated, with pricing around $500,000-$600,000 annually (U.S. estimates).[1][4]
[1]: Lamzede Prescribing Information (FDA)
[2]: Phase 3 Trial Results (NEJM, 2020)
[3]: ClinicalTrials.gov (NCT01548469)
[4]: Drugs.com Pricing